REGENXBIO Inc. (RGNX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenues | 21,359 | 89,012 | 24,197 | |
| Cost of goods and services sold, total | - | - | 12,387 | |
| Other operating expenses | - | - | 37 | |
| Research and development | 59,500 | 53,087 | 54,429 | |
| General and administrative | 19,883 | 20,347 | 19,422 | |
| Other operating expenses (income) | -45 | -15 | - | |
| Cost of license and royalty revenues | 5,209 | 3,436 | - | |
| Total operating expenses | 84,637 | 76,885 | 86,275 | |
| Loss from operations | -63,278 | 12,127 | -62,078 | |
| Investment income | 3,379 | 2,501 | 3,276 | |
| Interest expense | 10,993 | 8,570 | 820 | |
| Interest income from licensing | 21 | 25 | 25 | |
| Total other income (expense) | -7,593 | -6,044 | 2,481 | |
| Net loss | -70,871 | 6,083 | -59,597 | |
| Unrealized gain (loss) on available-for-sale securities, net | 12 | -21 | 1,684 | |
| Total other comprehensive income (loss) | 12 | -21 | 1,684 | |
| Comprehensive loss | -70,859 | 6,062 | -57,913 | |
| Earnings per share, basic | -1.38 | 0.12 | -1.17 | |
| Earnings per share, diluted | -1.38 | 0.12 | -1.17 | |
| Weighted average number of shares outstanding, basic | 51,483,000 | 51,362,000 | 50,800,000 | |
| Weighted average number of shares outstanding, diluted | 51,483,000 | 51,434,000 | 50,800,000 | |